Mapping Product Lifecycle to Implement Phase-Appropriate Comparability Strategies & Leverage Early Flexibility for Allogeneic Cell Therapies
- Initiating early product and process lifecycle mapping to identify optimal timing for changes while leveraging FDA guidelines emphasizing flexibility in early phases versus stringent late-stage expectations
- Implementing robust statistical justification strategies and collaborating with statisticians to overcome analytical challenges and support regulatory-compliant comparability assessments
- Applying risk management frameworks in stepwise approaches to tackle potential showstoppers early and facilitate smoother transitions throughout process development activities